# US 2026/0061067 A1 · Anti-cMet and Anti-EGFR Multispecific Antibody Drug Conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0061067 A1
- Document ID: US20260061067A1
- Status: Published application
- Kind: A1
- Application number: 19/277,531
- Filed: 2025-07-23
- Published: 2026-03-05
- Earliest claimed: 2024-07-24
- Assignees: BeOne Medicines I GmbH
- Applicants: BeOne Medicines I GmbH
- Inventors: CHARNG-SHENG TSAI; Mei-Hsuan TSAI; Maomao HE; Wei LUO; Zewei WANG; Renke LI; Xiaodong WEI; Ming JIANG; Liu XUE; Mengran QIAN
- Web page: https://patentgrep.com/patent/US20260061067A1

## CPC

- A61K 47/68037: {the drug being a camptothecin [CPT] or derivatives}
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6879: {the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/30: from tumour cells
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides antibody drug conjugates comprising antibodies and antigen-binding fragments thereof and a linker-payload, a pharmaceutical composition comprising the antibody drug conjugates, and use of the antibody drug conjugate for treating diseases or disorders. The antibodies or antigen-binding fragments thereof specifically bind to a first and second epitope of human cMET and to human EGFR. The diseases or disorders are EGFR/cMET-associated diseases or disorders.

## Claims

### Claim at position 1

1-81. (canceled)

### Claim 82

An antibody drug conjugate, comprising: a multispecific antibody or antigen-binding fragment thereof, comprising
a first antigen binding domain that specifically binds to a first epitope of human cMET;
a second antigen binding domain that specifically binds to a second epitope of human cMET; and
a third antigen binding domain that specifically binds to human EGFR;
wherein the first epitope is distinct from the second epitope, or wherein the first antigen binding domain does not compete with the second antigen binding domain for binding to cMET;
wherein the antibody drug conjugate has the Formula A-I:
or a pharmaceutically acceptable salt, solvate, or hydrate thereof wherein:
Ab is the multispecific antibody or antigen-binding fragment thereof;
C is a conjugator;
L is a linker;
P is a payload; and
n is from 1 to 15.

### Claim 83 (depends on 82)

The antibody drug conjugate of claim 82, wherein the first antigen binding domain that specifically binds to the first epitope of human cMET comprises:
(1) a heavy chain variable region that comprises: (a) a HCDR1 (Heavy Chain Complementarity Determining Region 1) of SEQ ID NO: 6, (b) a HCDR2 of SEQ ID NO: 7, (c) a HCDR3 of SEQ ID NO: 92 and a light chain variable region that comprises: (d) a LCDR1 (Light Chain Complementarity Determining Region 1) of SEQ ID NO: 66, (e) a LCDR2 of SEQ ID NO: 67, and (f) a LCDR3 of SEQ ID NO: 68;
(2) a heavy chain variable region that comprises: (a) a HCDR1 of SEQ ID NO: 6, (b) a HCDR2 of SEQ ID NO: 7, (c) a HCDR3 of SEQ ID NO: 90 and a light chain variable region that comprises: (d) a LCDR1 of SEQ ID NO: 66, (e) a LCDR2 of SEQ ID NO: 67, and (f) a LCDR3 of SEQ ID NO: 68; or
(3) a heavy chain variable region that comprises: (a) a HCDR1 of SEQ ID NO: 6, (b) a HCDR2 of SEQ ID NO: 7, (c) a HCDR3 of SEQ ID NO: 88 and a light chain variable region that comprises: (d) a LCDR1 of SEQ ID NO: 66, (e) a LCDR2 of SEQ ID NO: 67, and (f) a LCDR3 of SEQ ID NO: 68;

### Claim 84 (depends on 82)

The antibody drug conjugate of claim 82, wherein the first antigen binding domain that specifically binds to the first epitope of human cMET comprises:
(1) a heavy chain variable region (VH) comprising an amino acid sequence at least 95% identical to SEQ ID NO: SEQ ID NO: 173, and a light chain variable region (VL) comprising an amino acid sequence at least 95% identical to SEQ ID NO: 64; or
(2) a heavy chain variable region (VH) comprising an amino acid sequence at least 95% identical to SEQ ID NO: 174, and a light chain variable region (VL) comprising an amino acid sequence at least 95% identical to SEQ ID NO: 64.

### Claim 85 (depends on 82)

The antibody drug conjugate of claim 82, wherein the second antigen binding domain that specifically binds to the second epitope of human cMET comprises:
a heavy chain variable region that comprises: (a) a HCDR1 of SEQ ID NO: 56, (b) a HCDR2 of SEQ ID NO: 57, (c) a HCDR3 of SEQ ID NO: 58 and a light chain variable region that comprises: (d) a LCDR1 of SEQ ID NO: 66, (e) a LCDR2 of SEQ ID NO: 67, and (f) a LCDR3 of SEQ ID NO: 68.

### Claim 86 (depends on 82)

The antibody drug conjugate of claim 82, wherein the second antigen binding domain that specifically binds to the second epitope of human cMET comprises:
a heavy chain variable region (VH) comprising an amino acid sequence at least 95% identical to SEQ ID NO: 145, and a light chain variable region (VL) comprising an amino acid sequence at least 95% identical to SEQ ID NO: 64.

### Claim 87 (depends on 82)

The antibody drug conjugate of claim 82, wherein the third antigen binding domain that specifically binds to human EGFR comprises:
a heavy chain variable region that comprises: (a) a HCDR of SEQ ID NO: 155, (b) a HCDR2 of SEQ ID NO: 156, (c) a HCDR3 of SEQ ID NO: 157 and a light chain variable region that comprises: (d) a LCDR1 of SEQ ID NO: 158, (e) a LCDR2 of SEQ ID NO: 159, and (f) a LCDR3 of SEQ ID NO: 160.

### Claim 88 (depends on 82)

The antibody drug conjugate of claim 82, wherein the third antigen binding domain that specifically binds to human EGFR comprises a heavy chain variable region (VH) comprising an amino acid sequence at least 95% identical to SEQ ID NO: 142, and/or a light chain variable region (VL) comprising an amino acid sequence at least 95% identical to SEQ ID NO: 143.

### Claim 89 (depends on 82)

The antibody drug conjugate of claim 82, wherein
the first antigen binding domain that specifically binds to the first epitope of human cMET comprises: a heavy chain variable region that comprises: (a) a HCDR1 of SEQ ID NO: 6, (b) a HCDR2 of SEQ ID NO: 7, (c) a HCDR3 of SEQ ID NO: 90 and a light chain variable region that comprises: (d) a LCDR1 of SEQ ID NO: 66, (e) a LCDR2 of SEQ ID NO: 67, and (f) a LCDR3 of SEQ ID NO: 68;
the second antigen binding domain that specifically binds to the second epitope of human cMET comprises: a heavy chain variable region that comprises: (a) a HCDR1 of SEQ ID NO: 56, (b) a HCDR2 of SEQ ID NO: 57, (c) a HCDR3 of SEQ ID NO: 58 and a light chain variable region that comprises: (d) a LCDR1 of SEQ ID NO: 66, (e) a LCDR2 of SEQ ID NO: 67, and f a LCDR3 of SEQ ID NO: 68; and
the third antigen binding domain that specifically binds to human EGFR comprises: a heavy chain variable region that comprises: (a) a HCDR1 of SEQ ID NO: 155, (b) a HCDR2 of SEQ ID NO: 156, (c) a HCDR3 of SEQ ID NO: 157 and a light chain variable region that comprises: (d) a LCDR1 of SEQ ID NO: 158, (e) a LCDR2 of SEQ ID NO: 159, and (f) a LCDR3 of SEQ ID NO: 160.

### Claim 90 (depends on 82)

The antibody drug conjugate of claim 82, wherein
the first antigen binding domain that specifically binds to the first epitope of human cMET comprises: a heavy chain variable region that comprises: (a) a HCDR1 of SEQ ID NO: 6, (b) a HCDR2 of SEQ ID NO: 7, (c) a HCDR3 of SEQ ID NO: 92 and a light chain variable region that comprises: (d) a LCDR1 of SEQ ID NO: 66, (e) a LCDR2 of SEQ ID NO: 67, and (f) a LCDR3 of SEQ ID NO: 68;
the second antigen binding domain that specifically binds to the second epitope of human cMET comprises: a heavy chain variable region that comprises: (a) a HCDR1 of SEQ ID NO: 56, (b) a HCDR2 of SEQ ID NO: 57, (c) a HCDR3 of SEQ ID NO: 58 and a light chain variable region that comprises: (d) a LCDR1 of SEQ ID NO: 66, (e) a LCDR2 of SEQ ID NO: 67, and (f) a LCDR3 of SEQ ID NO: 68; and
the third antigen binding domain that specifically binds to human EGFR comprises: a heavy chain variable region that comprises: (a) a HCDR1 of SEQ ID NO: 155, (b) a HCDR2 of SEQ ID NO: 156, (c) a HCDR3 of SEQ ID NO: 157 and a light chain variable region that comprises: (d) a LCDR1 of SEQ ID NO: 158, (e) a LCDR2 of SEQ ID NO: 159, and (f) a LCDR3 of SEQ ID NO: 160.

### Claim 91 (depends on 82)

The antibody drug conjugate of claim 82, wherein
the first antigen binding domain that specifically binds to the first epitope of human cMET comprises: a heavy chain variable region that comprises: (a) a HCDR1 of SEQ ID NO: 6, (b) a HCDR2 of SEQ ID NO: 7, (c) a HCDR3 of SEQ ID NO: 88 and a light chain variable region that comprises: (d) a LCDR1 of SEQ ID NO: 66, (e) a LCDR2 of SEQ ID NO: 67, and f a LCDR3 of SEQ ID NO: 68;
the second antigen binding domain that specifically binds to the second epitope of human cMET comprises: a heavy chain variable region that comprises: (a) a HCDR1 of SEQ ID NO: 56, (b) a HCDR2 of SEQ ID NO: 57, (c) a HCDR3 of SEQ ID NO: 58 and a light chain variable region that comprises: (d) a LCDR1 of SEQ ID NO: 66, (e) a LCDR2 of SEQ ID NO: 67, and (f) a LCDR3 of SEQ ID NO: 68; and
the third antigen binding domain that specifically binds to human EGFR comprises: a heavy chain variable region that comprises: (a) a HCDR1 of SEQ ID NO: 155, (b) a HCDR2 of SEQ ID NO: 156, (c) a HCDR3 of SEQ ID NO: 157 and a light chain variable region that comprises: (d) a LCDR1 of SEQ ID NO: 158, (e) a LCDR2 of SEQ ID NO: 159, and (f) a LCDR3 of SEQ ID NO: 160.

### Claim 92 (depends on 82)

The antibody drug conjugate of claim 82, wherein
the first antigen binding domain that specifically binds to the first epitope of human cMET comprises: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 173, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 64;
the second antigen binding domain that specifically binds to the second epitope of human cMET comprises: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 145, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 64; and
the third antigen binding domain that specifically binds to human EGFR comprises: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 142, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 143.

### Claim 93 (depends on 82)

The antibody drug conjugate of claim 82, wherein
the first antigen binding domain that specifically binds to the first epitope of human cMET comprises: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 174, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 64;
the second antigen binding domain that specifically binds to the second epitope of human cMET comprises: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 145, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 64; and
the third antigen binding domain that specifically binds to human EGFR comprises: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 142, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 143.

### Claim 94 (depends on 82)

The antibody drug conjugate of claim 82, wherein
the first antigen binding domain that specifically binds to the first epitope of human cMET and the second antigen binding domain that specifically binds to the second epitope of human cMET comprise a bispecific IgG antibody, and wherein the third antigen binding domain that specifically binds to human EGFR comprises a single chain Fv (scFv),
wherein
(a) the scFv is attached to the C-terminal of a light chain of one or both of the first and second antigen binding domains;
(b) the scFv is attached to the N-terminal of a light chain of one or both of the first and second antigen binding domains;
(c) the scFv is attached to the N-terminal of a heavy chain of both of the first and second antigen binding domains;
(d) the scFv is attached to the N-terminal of a heavy chain of one of the first and second antigen binding domains;
(e) the scFv is attached to the C-terminal of a heavy chain constant region of one of the first and second antigen binding domains; or
(f) the scFv is attached to the C-terminal of a heavy chain constant region of both of the first and second antigen binding domains.

### Claim 95 (depends on 82)

The antibody drug conjugate of claim 82, wherein
the third antigen binding domain that specifically binds to human EGFR comprises a scFv comprising a VH comprising the amino acid sequence of SEQ ID NO: 142 and a VL comprising the amino acid sequence of SEQ ID NO: 143;
wherein the VH and VL are connected via a first amino acid linker;
wherein the first amino acid linker comprises the amino acid sequence of any one of SEQ ID NOs: 97-139.

### Claim 96 (depends on 95)

The antibody drug conjugate of claim 95, wherein the scFv comprises a first amino acid linker comprising the sequence of SEQ ID NO: 139 and wherein the third antigen binding domain that specifically binds to human EGFR comprises a scFv comprising the amino acid sequence of SEQ ID NO: 161.

### Claim 97 (depends on 82)

The antibody drug conjugate of claim 82, wherein the first antigen binding domain that specifically binds to the first epitope of human cMET and the second antigen binding domain that specifically binds to the second epitope of human cMET collectively comprise a bispecific IgG antibody that comprises a human IgG1, IgG2, IgG3, or IgG4 heavy chain constant region, and/or a human kappa or lambda light chain constant region, wherein the heavy chain constant region optionally lacks a C-terminal lysine or a C-terminal glycine-lysine.

### Claim 98 (depends on 82)

The antibody drug conjugate of claim 82, wherein the multispecific antibody or antigen-binding fragment thereof has antibody dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) or complement dependent cytotoxicity (CDC).

### Claim 99 (depends on 82)

The antibody drug conjugate of claim 82, comprising a first polypeptide, a second polypeptide, and a third polypeptide, wherein
(1) the first polypeptide comprises the amino acid sequence of SEQ ID NO: 153, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 150, and the third polypeptide comprises the amino acid sequence of SEQ ID NO: 148;
(2) the first polypeptide comprises the amino acid sequence of SEQ ID NO: 168, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 169, and the third polypeptide comprises the amino acid sequence of SEQ ID NO: 148;
(3) the first polypeptide comprises the amino acid sequence of SEQ ID NO: 153, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 170, and the third polypeptide comprises the amino acid sequence of SEQ ID NO: 148;
(4) the first polypeptide comprises the amino acid sequence of SEQ ID NO: 168, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 171, and the third polypeptide comprises the amino acid sequence of SEQ ID NO: 148; or
(5) the first polypeptide comprises the amino acid sequence of SEQ ID NO: 153, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 172, and the third polypeptide comprises the amino acid sequence of SEQ ID NO: 148.

### Claim 100 (depends on 82)

The antibody drug conjugate of claim 82, wherein the antibody drug conjugate has Formula (I):
or a pharmaceutically acceptable salt, tautomer, solvate, or stereoisomer thereof, wherein:
BA is Ab;
Z′ is
wherein * indicates the bond where Z′ attaches to BA;
X is a substituted or unsubstituted C5 alkyl;
W is oxygen;
w′ is 0 or 1;
c′ is 1 or 2;
a′ is 1, 2, or 3;
each A is, independently, an amino acid residue optionally substituted with a hydrophilic group;
P is a payload residue; and
n is from 1 to 15.

### Claim 101 (depends on 100)

The antibody drug conjugate of claim 100, wherein X is —(CH2)3—, —(CH2)5—, —CH(CH2NH2)(CH2)2—, —CH(CH2NH2)(CH2)4—, —CH2CH1(NH2)CH2—, CH(CH2NH2)CH2—, or —CH(CH2NH2)(CH2)2—.

### Claim 102 (depends on 101)

The antibody drug conjugate of claim 101, wherein A is substituted with a hydrophilic group (HG) and HG is:

### Claim 103 (depends on 101)

The antibody drug conjugate of claim 101, wherein A is
wherein HG is a hydrophilic group.

### Claim 104 (depends on 101)

The antibody drug conjugate of claim 101, wherein A is
or wherein A is

### Claim 105 (depends on 82)

The antibody drug conjugate of claim 82, wherein P is:

### Claim 106 (depends on 82)

The antibody drug conjugate of claim 82, wherein the antibody drug conjugate is represented by one of the following formulas:
or a pharmaceutically acceptable salt, solvate, and/or stereoisomer thereof, wherein n is from 3 to 12.

### Claim 107 (depends on 82)

The antibody drug conjugate of claim 82, wherein the antibody drug conjugate comprises one of the following formulas:
or a pharmaceutically acceptable salt, solvate, and/or stereoisomer thereof, wherein the Ab comprises a first polypeptide comprising the amino acid sequence of SEQ ID NO: 153, a second polypeptide comprising the amino acid sequence of SEQ ID NO: 170, and a third polypeptide comprising the amino acid sequence of SEQ ID NO: 148;
or a pharmaceutically acceptable salt, solvate, and/or stereoisomer thereof, wherein the Ab comprises a first polypeptide comprising the amino acid sequence of SEQ ID NO: 153, a second polypeptide comprising the amino acid sequence of SEQ ID NO: 172, and a third polypeptide comprising the amino acid sequence of SEQ ID NO: 148;
or a pharmaceutically acceptable salt, solvate, and/or stereoisomer thereof, wherein the Ab comprises a first polypeptide comprising the amino acid sequence of SEQ ID NO: 153, a second polypeptide comprising the amino acid sequence of SEQ ID NO: 150, and a third polypeptide comprising the amino acid sequence of SEQ ID NO: 148;
or a pharmaceutically acceptable salt, solvate, and/or stereoisomer thereof, wherein the Ab comprises a first polypeptide comprising the amino acid sequence of SEQ ID NO: 168, a second polypeptide comprising the amino acid sequence of SEQ ID NO: 169, and a third polypeptide comprising the amino acid sequence of SEQ ID NO: 148;
or a pharmaceutically acceptable salt, solvate, and/or stereoisomer thereof, wherein the Ab comprises a first polypeptide comprising the amino acid sequence of SEQ ID NO: 168, a second polypeptide comprising the amino acid sequence of SEQ ID NO: 171, and a third polypeptide comprising the amino acid sequence of SEQ ID NO: 148; or
or a pharmaceutically acceptable salt, solvate, and/or stereoisomer thereof, wherein the Ab comprises a first polypeptide comprising the amino acid sequence of SEQ ID NO: 168, a second polypeptide comprising the amino acid sequence of SEQ ID NO: 171, and a third polypeptide comprising the amino acid sequence of SEQ ID NO: 148.

### Claim 108 (depends on 82)

A pharmaceutical composition comprising the antibody drug conjugate of claim 82 and a pharmaceutically acceptable carrier.

### Claim 109 (depends on 108)

A method of treating a cancer comprising administering to a patient in need a therapeutically effective amount of the pharmaceutical composition of claim 108.

### Claim 110 (depends on 109)

The method of claim 109, wherein the cancer is non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC).

### Claim 111 (depends on 82)

A process for producing the antibody drug conjugate of claim 82 comprising:
(i) culturing a host cell that has been transformed by an isolated nucleic acid comprising one or more sequences encoding the multispecific antibody or antigen-binding fragment thereof;
(ii) expressing the multispecific antibody or antigen-binding fragment thereof;
(iii) recovering the expressed multispecific antibody or antigen-binding fragment thereof; and
(iv) conjugating the payload (P) to the multispecific antibody or fragment thereof using the linker (L) and conjugator (C), such that the antibody drug conjugate is formed.
